Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Edgardo S. Santos. (2020) Treatment options after first-line immunotherapy in metastatic NSCLC. Expert Review of Anticancer Therapy 20:3, pages 221-228.
Read now
Read now
Giuseppe Bronte, Enrico Bronte, Giuseppina Novo, Gianfranco Pernice, Francesca Lo Vullo, Emmanuela Musso, Fabrizio Bronte, Eliana Gulotta, Sergio Rizzo, Christian Rolfo, Nicola Silvestris, Viviana Bazan, Salvatore Novo & Antonio Russo. (2015) Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opinion on Drug Safety 14:2, pages 253-267.
Read now
Read now
Giuseppe Bronte, Francesca Lo Vullo, Gianfranco Pernice, Antonio Galvano, Eugenio Fiorentino, Giuseppe Cicero, Viviana Bazan, Christian Rolfo & Antonio Russo. (2015) Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy. Expert Opinion on Investigational Drugs 24:1, pages 125-132.
Read now
Read now
Francesca Bedussi, Alberto Bottini, Maurizio Memo, Stephen B Fox, Sandra Sigala & Daniele Generali. (2014) Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?. Expert Opinion on Therapeutic Targets 18:6, pages 665-678.
Read now
Read now
Articles from other publishers (24)
Avinash Khadela, Humzah Postwala, Deval Rana, Hetvi Dave, Ketan Ranch & Sai H. S. Boddu. (2023) A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer. Medical Oncology 40:5.
Crossref
Crossref
Yinhui Hang, Yanfang Liu, Zhaogang Teng, Xiongfeng Cao & Haitao Zhu. (2023) Mesoporous nanodrug delivery system: a powerful tool for a new paradigm of remodeling of the tumor microenvironment. Journal of Nanobiotechnology 21:1.
Crossref
Crossref
Abdalla R. Mohamed & Ahmed M. El Kerdawy. (2022) A Perspective Study on the RTK, PI3K, B‐Raf, CDK and the Multi‐Protein Targeting in Medicinal Chemistry. Chemistry & Biodiversity 19:10.
Crossref
Crossref
Xiaofeng Du, Donald P. McManus, Conor E. Fogarty, Malcolm K. Jones & Hong You. (2022) Schistosoma mansoni Fibroblast Growth Factor Receptor A Orchestrates Multiple Functions in Schistosome Biology and in the Host-Parasite Interplay. Frontiers in Immunology 13.
Crossref
Crossref
Jonathan Thomas & Guru Sonpavde. (2022) Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. Cancers 14:7, pages 1795.
Crossref
Crossref
José F. Rodríguez, Anji Zhang, Jonathan Bajohr, Andrew Whyte, Bijan Mirabi & Mark Lautens. (2021) Cycloisomerization of Carbamoyl Chlorides in Hexafluoroisopropanol: Stereoselective Synthesis of Chlorinated Methylene Oxindoles and Quinolinones. Angewandte Chemie International Edition 60:34, pages 18478-18483.
Crossref
Crossref
José F. Rodríguez, Anji Zhang, Jonathan Bajohr, Andrew Whyte, Bijan Mirabi & Mark Lautens. (2021) Cycloisomerization of Carbamoyl Chlorides in Hexafluoroisopropanol: Stereoselective Synthesis of Chlorinated Methylene Oxindoles and Quinolinones. Angewandte Chemie 133:34, pages 18626-18631.
Crossref
Crossref
Alexandru Tirpe, Diana Gulei, George Razvan Tirpe, Andreea Nutu, Alexandru Irimie, Paola Campomenosi, Laura Ancuta Pop & Ioana Berindan-Neagoe. (2020) Beyond Conventional: The New Horizon of Anti-Angiogenic microRNAs in Non-Small Cell Lung Cancer Therapy. International Journal of Molecular Sciences 21:21, pages 8002.
Crossref
Crossref
Zhiyong Wang, Huan Xu, Junai Zhang, Hua Jin & Pei Wei. (2019) Basic fibroblast growth factor blockade enhances lung cancer cell invasion by activating the AKT/MMP‐2/VEGF pathway. Basic & Clinical Pharmacology & Toxicology 126:1, pages 43-50.
Crossref
Crossref
Nachiket Kamatkar, Matthew Levy & Jean M. Hébert. (2019) Development of a Monomeric Inhibitory RNA Aptamer Specific for FGFR3 that Acts as an Activator When Dimerized. Molecular Therapy - Nucleic Acids 17, pages 530-539.
Crossref
Crossref
Behzad Jafari, Maryam Hamzeh-Mivehroud, Michael B. Morris & Siavoush Dastmalchi. (2019) Exploitation of phage display for the development of anti-cancer agents targeting fibroblast growth factor signaling pathways: New strategies to tackle an old challenge. Cytokine & Growth Factor Reviews 46, pages 54-65.
Crossref
Crossref
Akihiro Nishiyama, Tadaaki Yamada, Kenji Kita, Rong Wang, Sachiko Arai, Koji Fukuda, Azusa Tanimoto, Shinji Takeuchi, Shoichiro Tange, Atsushi Tajima, Noritaka Furuya, Takayoshi Kinoshita & Seiji Yano. (2018)
Foretinib Overcomes Entrectinib Resistance Associated with the
NTRK1
G667C Mutation in
NTRK1
Fusion–Positive Tumor Cells in a Brain Metastasis Model
. Clinical Cancer Research 24:10, pages 2357-2369.
Crossref
Crossref
Luis Corrales, Amanda Nogueira, Francesco Passiglia, Angela Listi, Christian Caglevic, Marco Giallombardo, Luis Raez, Edgardo Santos & Christian Rolfo. (2017) Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. Frontiers in Medicine 4.
Crossref
Crossref
Helmut H. Popper, Ulrike Gruber-Mösenbacher, Georg Hutarew, Maximilian Hochmair, Gudrun Absenger, Luka Brcic, Leonhard Müllauer, Gerhard Dekan, Ulrike Setinek, Dagmar Krenbek, Michael Vesely, Robert Pirker, Wolfgang Hilbe, Rainer Kolb, Gerald Webersinke, Tamara Hernler, Georg Pall, Sigurd Lax & Andrea Mohn-Staudner. (2016) Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer. memo - Magazine of European Medical Oncology 9:4, pages 191-200.
Crossref
Crossref
Giuseppe Bronte, Lorena Incorvaia, Sergio Rizzo, Francesco Passiglia, Antonio Galvano, Fabio Rizzo, Christian Rolfo, Daniele Fanale, Angela Listì, Clara Natoli, Viviana Bazan & Antonio Russo. (2016) The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. Critical Reviews in Oncology/Hematology 107, pages 20-32.
Crossref
Crossref
Omar Abdel-Rahman, Nermean Bahie Eldin & Hesham ElHalawani. (2016) Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis. Future Oncology 12:18, pages 2163-2172.
Crossref
Crossref
Giuseppe Bronte, Tindara Franchina, Massimiliano Alù, Giovanni Sortino, Claudia Celesia, Francesco Passiglia, Giuseppina Savio, Agata Laudani, Alessandro Russo, Antonio Picone, Sergio Rizzo, Michele De Tursi, Elisabetta Gambale, Viviana Bazan, Clara Natoli, Livio Blasi, Vincenzo Adamo & Antonio Russo. (2016) The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. Oncotarget 7:24, pages 35803-35812.
Crossref
Crossref
Joan Minguet, Katherine H. Smith & Peter Bramlage. (2016) Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives. International Journal of Cancer 138:11, pages 2549-2561.
Crossref
Crossref
Giuseppe Bronte, Francesco Passiglia, Antonio Galvano, Nadia Barraco, Angela Listì, Marta Castiglia, Sergio Rizzo, Eugenio Fiorentino, Viviana Bazan & Antonio Russo. (2016) Nintedanib in NSCLC: evidence to date and place in therapy. Therapeutic Advances in Medical Oncology 8:3, pages 188-197.
Crossref
Crossref
F. de Braud, S. Cascinu, G. Spitaleri, K. Pilz, L. Clementi, D. Liu, P. Sikken & T. De Pas. (2015) A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. Annals of Oncology 26:11, pages 2341-2346.
Crossref
Crossref
Christian Caglevic, Massimiliano Grassi, Luis Raez, Angela Listi, Marco Giallombardo, Eva Bustamante, Ignacio Gil-Bazo & Christian Rolfo. (2015) Nintedanib in non-small cell lung cancer: from preclinical to approval. Therapeutic Advances in Respiratory Disease 9:4, pages 164-172.
Crossref
Crossref
G.V. Scagliotti, P. Bironzo & J.F. Vansteenkiste. (2015) Addressing the unmet need in lung cancer: The potential of immuno-oncology. Cancer Treatment Reviews 41:6, pages 465-475.
Crossref
Crossref
Chao Ding, Cunlong Zhang, Mingli Zhang, Yu Zong Chen, Chunyan Tan, Ying Tan & Yuyang Jiang. (2014) Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. Future Medicinal Chemistry 6:16, pages 1771-1789.
Crossref
Crossref
Giuseppe Aprile, Marta Bonotto, Elena Ongaro, Carmelo Pozzo & Francesco Giuliani. (2013) Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use. Drugs 73:18, pages 2003-2015.
Crossref
Crossref